Phase 3 results show the investigational drug norucholic acid is superior to placebo in halting disease progression.

In the pivotal, Phase III NUC-5 trial, (NCT03872921), NCA showed statistical superiority over placebo in achieving the ...

Morningstar brands and products Company Portfolio ...

today announced that the Company plans to highlight new research supporting its lead development candidates for the treatment of primary sclerosing cholangitis (PSC), a rare and progressive liver ...

Ipsen’s elafibranor has shown promise as a treatment for primary sclerosing cholangitis (PSC), a rare liver disease that currently has no approved treatment options. Results from the phase 2 ELMWOOD ...